Menstrual migraine

Current Treatment Options in Neurology

Volumn 6, Issue 6, 2004, Pages 489-498

  Mannix, Lisa K ^a   Calhoun, Anne H ^b  

^a Headache Associates   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; CAFFEINE; ELETRIPTAN; ESTRADIOL; ETHINYLESTRADIOL; FROVATRIPTAN; IBUPROFEN; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN; PYROGLUTAMATE MAGNESIUM; RIZATRIPTAN; ROFECOXIB; SEROTONIN AGONIST; SUMATRIPTAN SUCCINATE; VITAMIN; ZOLMITRIPTAN;

ANALGESIA; CLINICAL TRIAL; COMORBIDITY; DIETARY INTAKE; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG HALF LIFE; DYSMENORRHEA; ENDOMETRIOSIS; EXERCISE; FEMALE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; LIFESTYLE; MENSTRUAL CYCLE; MENSTRUATION; META ANALYSIS; METRORRHAGIA; MIGRAINE; PATIENT COMPLIANCE; PHYSICAL DISABILITY; REVIEW; SALPINGOOOPHORECTOMY; SLEEP; SMOKING CESSATION; STRESS; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 9244244703     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-004-0006-7     Document Type: Review

References (59)

1. Silberstein SD, Merriam GR: Sex hormones and headache. J Pain Symptom Manage 1993, 8:243-259.
2. Lipton RB, Stewart WF, Diamond S, et al.: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646-657.
3. Bille BS: Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr 1962, 51(suppl 136 ):1-151.
4. Waters WE: Epidemiology of headache and migraine in women. J Neurol Neurosurg Psychiatry 1971, 34:148-153.
5. Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992, 267:64-69.
6. Epstein MT, Hockaday JM, Hockaday TD: Migraine and reporoductive hormones throughout the menstrual cycle. Lancet 1975, 1:543-548.
7. Neri I, Granella F, Nappi R, et al.: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993, 17:31-37.
8. Lay CL, Newman LC: Menstrual migraine: approaches to management. CNS Drugs 1999, 12:189-195.
9. Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999, 53:537-542.
10. Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 (suppl 1): -160.
11. Edelson RN: Menstrual migraine and other hormonal aspects of migraine. Headache 1985, 25:376-379.
12. Couturier EG, Bomhof MA, Neven AK, van Duijn NP: Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003, 23:302-308.
13. Stewart WF, Lipton RB, Chee E, et al.: Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000, 55:1517-1523.
14. Schoenen J, Sawyer J: Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 1997, 17(suppl 18):28-40.
15. Salonen R, Saiers J: Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analysis. Cephalalgia 1999, 19:16-19.
16. Silberstein SD, Massiou H, Le Jeunne C, et al.: Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000, 96:237-242.
17. Loder E: Prophylaxis of menstrual migraine with triptans: problems and possibilities. Neurology 2002, 59:1677-1681.
18. Paiva T, Farinha A, Martins A, et al.: Chronic headaches and sleep disorders. Arch Intern Med 1997, 157: 701-1705.
19. Baker FC, Driver HS: Self-reported sleep across the menstrual cycle in young, healthy women. J Psychosom Res 2004, 56:239-243.
20. Hollander LE, Freeman EW, Sammel MD, et al.: M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol 2001, 98:391-397.
21. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. The American Academy of Neurology. Available at: http://www.ahsnet.org/guidelines.php. Accessed June, 2004.
22. Lipton RB, Stewart WF, Ryan RE Jr, et al.: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol Feb 1998, 55: 10-217.
23. Silberstein SD, Lipton RB, Goadsby PJ, eds: Headache in Clinical Practice. Oxford: ISIS Medical Media; 1998
24. Silberstein S, Tepper S, Brandes J, et al.: Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004, 62:1552-1557.
25. Rapoport AM, Sheftell FD: Headache Disorders: A management Guide for Practitioners. Philadelphia: WB Saunders Company; 1996.
26. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD: The triptan formulations: how to match patients and products. CNS Drugs 2003, 17:431-447.
27. Axert [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2003
28. Imitrex [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2004
29. Zomig [prescribing information]. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2003
30. Maxalt [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc; 2003.
31. Frova [prescribing information]. Craigavon, United Kingdom: Galen, Limited; 2001.
32. Amerge [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2003
33. Relpax [prescribing information]. New York, NY: Pfizer; 2003.
34. Nett R, Landy S, Shackelford S, Richardson MS, et al.: Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003, 102:835-842.
35. Silberstein S: The efficacy of zolmitriptan is unaffected by the relationship to menses. Paper presented at the 10th Congress of the International Headache Society. New York, NY; June 20-July 2, 2001.
36. Loder E, Silberstein SD, Abu-Shakra S, et al.: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004, 44:120-130.
37. Massiou H, Silberstein S, Le Jeunne C, et al.: Efficacy of rizatriptan in menstrual migraine: Freedom from pain and associated symptoms at 2-h and 24-h sustained pain-free status. Cephalalgia 2000, 20:343-344.
38. Silberstein SD, Massiou H, McCarroll KA, Lines CR: Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002, 42:917-923.
39. MacGregor EA, Keywood C: Frovatriptan is effective in menstrually associated migraine (abstract). Cephalalgia 2000, 20:338-357.
40. Hettiarachi J, Pitei D: Oral Eletriptan is effective in treating menstrually-associated migraine and women on oral contraceptives or hormone replacement therapy. Paper presented at: 42nd Meeting of the American Headache Society. Montreal, Canada; 2002.
41. Sances G, Martignoni E, Fioroni L, et al.: Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990, 30:705-709.
42. Von Seggern RL, Mannix LK, Adelman JU: Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial. Headache 2004, 44:160-165.
43. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307-309.
44. Newman LC, Mannix LK, Sandy S, et al.: Naratriptan as short-term prophylaxis of menstrually-associated migraine: A randomized, double-blind, placebo-controlled study. Headache 2001, 41:248-256.
45. Brandes JL, Smith T: Naratriptan 1 mg BID in the prophylactic treatment of menstrually-associated migraine. Paper presented at the 44th Annual Meeting of the American Headache Society. Seattle, WA; June 18-22, 2002.
46. Savani N, Loftus J, Mansbach H, Scot A: A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 6th European Headache Congress. Istanbul, Turkey; June 17-22, 2002.
47. Nett R, Mannix L, Sandy S, et al.: Randomized, double-blind, placebo-controlled parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 55th Annual Meeting of the American Academy of Neurology. Honolulu, HI; March 29-April 5, 2003.
48. Silberstein SD, Elkind AH, Schreiber C: Frovatriptan, a selective HT1B/1D agonist, is effective for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(Suppl 1 : 94.
49. Smith T, Nett R: Frovatriptan is well tolerated during repeated use for prophylaxis of menstrually associated migraine (abstract). Headache 2003, 43:586.
50. Spierings ELH, Couch R, Blumenthal HJ: Clinical characteristics of menstrually associated migraine: a review of results from a study of the use of frovatriptan for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(suppl 1 : 493.
51. Tepper S, Freitag F: Prophylactic use of frovatriptan for menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period (abstract). Headache 2003, 43:585.
52. Goldstein J, Ninan M, Rapoport AM: The safety and tolerability of frovatriptan, a selective 5HT1B/1D agonist, used for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60 (Suppl 1):A494.
53. Singer R, Schim J: Frovatriptan for prophylaxis of menstrually associated migraine: efficacy and tolerability in patients using oral contraceptives compared to nonusers (abstract). Headache 2003, 43:587.
54. Calhoun A: Four hypotheses for understanding menstrual migraine. The Female Patient. 2004, 29:38-44.
55. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996, 348:498-505.
56. Petitti DB, Sidney S, Bernstein A, et al.: Stroke in users of low-dose oral contraceptives. N Engl J Med 1996, 335:8-15.
57. Chan WS, Ray J, Wai EK, et al.: Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004, 164:741-747.
58. Calhoun AH: Migraine and menopause. Headache 2004, 44:106.
59. Facchinetti F, Sances G, Borella P, et al.: Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991, 31:298-301.